<DOC>
	<DOC>NCT00883896</DOC>
	<brief_summary>The primary objective of this study is to assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active rheumatoid arthritis who are taking methotrexate.</brief_summary>
	<brief_title>Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Meets the American College of Rheumatology (ACR) 1987 revised criteria for classification of Rheumatoid Arthritis (RA) for at least 6 months prior to screening Active RA at the time of screening and baseline consisting of &gt;= 5 swollen and &gt;= 5 tender joints (28joint count) and at least 1 of the following at screening: Creactive protein &gt;= 10 mg/L or Erythrocyte Sedimentation Rate &gt;= 28 mm/h Must be receiving methotrexate for at least 12 weeks, with a stable route and dose (up to 25 mg weekly) for at least 8 weeks prior to the baseline visit. Subjects with other rheumatic diseases Cancer or history of cancer (other than cutaneous basal cell carcinoma and squamous cell carcinoma or in situ cervical cancer) Any prior use of B celldepleting therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>ACR</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Interleukin-22</keyword>
</DOC>